{
  "company": {
    "ticker": "GILD",
    "name": "Gilead Sciences Inc.",
    "category": [
      "Biotech"
    ],
    "sector": "Healthcare",
    "subCategory": "Biotech",
    "cik": "0000882095"
  },
  "reports": [
    {
      "filing": {
        "accessionNumber": "0000882095-25-000047",
        "filingDate": "2025-11-07",
        "reportDate": "2025-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209525000047/gild-20250930.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "strong",
        "headcountTrend": "freezing",
        "revenue": 7769,
        "netIncome": 3052,
        "operatingCashFlow": 6692,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "Negotiated settlement agreements with generic manufacturers that prevent generic entry of Biktarvy until 2035-2036",
        "customerConcentration": 60,
        "geographicBreakdown": {
          "US": 68,
          "Europe": 20,
          "RestOfWorld": 12
        },
        "capexAmount": 358,
        "capexGrowth": null,
        "partnerships": [
          "LEO Pharma - STAT6 program partnership",
          "Galapagos - amended collaboration agreement",
          "Arcus - continued collaboration"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Patent litigation with generic manufacturers",
          "Product liability lawsuits"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": true,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Gilead delivered strong Q3 2025 results with robust revenue of $7.8 billion and net income of $3.1 billion, driven by continued strength in HIV and oncology portfolios. The company successfully defended key patents and maintained a positive outlook through strategic partnerships and settlements.",
        "keyQuotes": [
          "Settlement agreements with generic manufacturers prevent generic entry of Biktarvy until 2035-2036",
          "Strategic partnership with LEO Pharma to develop STAT6 programs for inflammatory diseases"
        ],
        "marketData": {
          "priceOnEarningsDate": 111,
          "priceAfter7Days": 116.77999877929688,
          "priceChangePercent": 5.207206107474662,
          "managementToneScore": 100,
          "earningsBeatScore": 50,
          "priceActionScore": 70,
          "guidanceAccuracyScoreWeighted": 75,
          "compositeSentimentScore": 66,
          "compositeSentiment": "bullish"
        }
      },
      "quarter": "Q3 2025",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2025,
        "fiscalQuarter": 3,
        "fiscalYear": 2025,
        "quarter": "Q3 2025",
        "reportDate": "2025-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-25-000032",
        "filingDate": "2025-08-07",
        "reportDate": "2025-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209525000032/gild-20250630.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "freezing",
        "revenue": 7054,
        "netIncome": 1960,
        "operatingCashFlow": 2584,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 71.4,
          "Europe": 16.7,
          "RestOfWorld": 11.9
        },
        "capexAmount": 211,
        "capexGrowth": null,
        "partnerships": [
          "LEO Pharma - STAT6 oral programs",
          "Galapagos potential company separation"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "FDA clinical hold on HIV treatment trials",
          "Ongoing patent litigation with generic manufacturers"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Gilead delivered solid Q2 2025 financial performance with product sales of $7.054 billion and net income of $1.96 billion. The company continues to focus on innovative medicines in virology, oncology, and strategic partnerships while managing ongoing legal challenges.",
        "keyQuotes": [
          "Committed to advancing innovative medicines to prevent and treat life-threatening diseases",
          "Received FDA approval for Yeztugo, the first and only twice-yearly HIV PrEP option"
        ],
        "marketData": {
          "priceOnEarningsDate": 110.87000274658203,
          "priceAfter7Days": 111.77999877929688,
          "priceChangePercent": 0.8207774963213822,
          "managementToneScore": 90,
          "earningsBeatScore": 50,
          "priceActionScore": 55,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 56,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q2 2025",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2025,
        "fiscalQuarter": 2,
        "fiscalYear": 2025,
        "quarter": "Q2 2025",
        "reportDate": "2025-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-25-000012",
        "filingDate": "2025-05-07",
        "reportDate": "2025-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209525000012/gild-20250331.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "reducing",
        "revenue": 6667,
        "netIncome": 1315,
        "operatingCashFlow": 1757,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 70,
          "Europe": 16,
          "RestOfWorld": 14
        },
        "capexAmount": 104,
        "capexGrowth": null,
        "partnerships": [
          "LEO Pharma collaboration on STAT6 programs",
          "Ongoing Galapagos collaboration",
          "Galapagos NV",
          "LEO Pharma A/S",
          "Arcus Biosciences Inc",
          "CymaBay",
          "Immunomedics Inc",
          "Arcellx Inc"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Medicare Part D redesign impact"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": true,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Gilead delivered stable Q1 2025 performance with HIV product sales growing 6% driven by Biktarvy demand and higher pricing. Net income rebounded to $1.3B compared to prior year loss, aided by reduced one-time charges. Research expenses declined and the company continues strategic collaborations.",
        "keyQuotes": [
          "We are committed to advancing innovative medicines to prevent and treat life-threatening diseases",
          "HIV product sales increased 6% primarily due to higher demand and higher average realized price"
        ],
        "marketData": {
          "priceOnEarningsDate": 112.05000305175781,
          "priceAfter7Days": 105.5199966430664,
          "priceChangePercent": -5.827761027079209,
          "managementToneScore": 90,
          "earningsBeatScore": 50,
          "priceActionScore": 25,
          "guidanceAccuracyScoreWeighted": 75,
          "compositeSentimentScore": 52,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q1 2025",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2025,
        "fiscalQuarter": 1,
        "fiscalYear": 2025,
        "quarter": "Q1 2025",
        "reportDate": "2025-03-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-25-000006",
        "filingDate": "2025-02-28",
        "reportDate": "2024-12-31",
        "form": "10-K",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/gild-20241231.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": 6,
        "pricingPower": "moderate",
        "headcountTrend": "stable",
        "revenue": 7611,
        "netIncome": 1783,
        "operatingCashFlow": 10828,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "8% HIV product sales growth, primarily due to higher demand and higher average realized price",
        "customerConcentration": 90,
        "geographicBreakdown": {
          "US": 71.4,
          "Europe": 16.1,
          "RestOfWorld": 12.5
        },
        "capexAmount": null,
        "capexGrowth": null,
        "partnerships": [
          "LEO Pharma A/S collaboration",
          "Arcus Biosciences collaboration",
          "Janssen Pharmaceutica NV royalty buyout",
          "Cardinal Health",
          "Cencora",
          "McKesson Corp"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Inflation Reduction Act impacts",
          "Potential Medicare price negotiations",
          "State prescription drug affordability reviews"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "neutral",
        "summary": "Gilead delivered 6% revenue growth in 2024, driven by HIV, Oncology and Liver Disease product sales. The company faced challenges with Trodelvy impairment charges and continued COVID-19 sales decline, but maintains a strong pipeline of over 100 pre-clinical and clinical-stage programs.",
        "keyQuotes": [
          "We expect to see continued increases in demand for our products overall, bolstered by the growth of our HIV business",
          "Our R&D portfolio includes over 100 pre-clinical and clinical-stage programs across our core therapeutic areas"
        ],
        "marketData": {
          "priceOnEarningsDate": 92.37000274658203,
          "priceAfter7Days": 90.62999725341797,
          "priceChangePercent": -1.8837343741753303,
          "managementToneScore": 65,
          "earningsBeatScore": 50,
          "priceActionScore": 45,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 50,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q4 2024",
      "quarterInfo": {
        "calendarQuarter": 4,
        "calendarYear": 2024,
        "fiscalQuarter": 4,
        "fiscalYear": 2024,
        "quarter": "Q4 2024",
        "reportDate": "2024-12-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-24-000028",
        "filingDate": "2024-11-12",
        "reportDate": "2024-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209524000028/gild-20240930.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "not_provided",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "reducing",
        "revenue": 7545,
        "netIncome": 1253,
        "operatingCashFlow": 7853,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "Defending patents for key HIV products like Biktarvy against generic challenges",
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 72.3,
          "Europe": 15.5,
          "RestOfWorld": 12.3
        },
        "capexAmount": 376,
        "capexGrowth": null,
        "partnerships": [
          "Arcellx collaboration for multiple myeloma therapy",
          "Arcus collaboration",
          "CymaBay acquisition"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Patent litigation for HIV drugs",
          "Product liability lawsuits",
          "Potential FDA challenges"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "defensive",
        "overallSentiment": "neutral",
        "summary": "Gilead reported quarterly revenue of $7.5B and net income of $1.25B, with strong performance in HIV products. The company is facing patent challenges and restructuring its workforce while pursuing strategic collaborations and acquisitions.",
        "keyQuotes": [
          "We intend to vigorously defend ourselves in these actions",
          "Gilead reached an agreement to make a one-time payment of up to $40 million to a group of eligible plaintiffs"
        ],
        "marketData": {
          "priceOnEarningsDate": 83.83999633789062,
          "priceAfter7Days": 84.43000030517578,
          "priceChangePercent": 0.703726136756175,
          "managementToneScore": 25,
          "earningsBeatScore": 50,
          "priceActionScore": 55,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 49,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q3 2024",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2024,
        "fiscalQuarter": 3,
        "fiscalYear": 2024,
        "quarter": "Q3 2024",
        "reportDate": "2024-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-24-000022",
        "filingDate": "2024-08-08",
        "reportDate": "2024-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209524000022/gild-20240630.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "reducing",
        "revenue": 6912,
        "netIncome": 1614,
        "operatingCashFlow": 3544,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 71.1,
          "Europe": 16.1,
          "RestOfWorld": 12.8
        },
        "capexAmount": 235,
        "capexGrowth": null,
        "partnerships": [
          "Merus N.V. collaboration for oncology trispecific T-cell engagers",
          "Xilio Therapeutics license for tumor-activated IL-12 program",
          "Janssen Pharmaceutica royalty buy-out for seladelpar"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "neutral",
        "overallSentiment": "neutral",
        "summary": "Gilead reported steady quarterly performance with 5% revenue growth, driven by HIV, Oncology, and Liver Disease product sales. The company is focused on strategic acquisitions like CymaBay and managing operational expenses through workforce reductions.",
        "keyQuotes": [
          "We are committed to advancing innovative medicines to prevent and treat life-threatening diseases",
          "We received approval from FDA to expand Biktarvy's label to include treatment of people with HIV who have suppressed viral loads"
        ],
        "marketData": {
          "priceOnEarningsDate": 68.63999938964844,
          "priceAfter7Days": 67.55000305175781,
          "priceChangePercent": -1.5879900168749226,
          "managementToneScore": 45,
          "earningsBeatScore": 50,
          "priceActionScore": 45,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 48,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q2 2024",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2024,
        "fiscalQuarter": 2,
        "fiscalYear": 2024,
        "quarter": "Q2 2024",
        "reportDate": "2024-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-24-000013",
        "filingDate": "2024-05-08",
        "reportDate": "2024-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209524000013/gild-20240331.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "not_provided",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "reducing",
        "revenue": 6686,
        "netIncome": -4170,
        "operatingCashFlow": 2219,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "Higher HIV, Oncology and Liver Disease sales",
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": 69.3,
          "Europe": 17.3,
          "RestOfWorld": 13.4
        },
        "capexAmount": 105,
        "capexGrowth": null,
        "partnerships": [
          "Research collaboration with Merus N.V.",
          "License agreement with Xilio Therapeutics",
          "Acquired CymaBay Therapeutics"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Patent litigation with generic manufacturers",
          "FDA approval processes"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "defensive",
        "overallSentiment": "bearish",
        "summary": "Gilead reported a challenging Q1 2024 with a significant net loss driven by R&D charges from CymaBay acquisition and an impairment. While product sales grew 5%, substantial one-time expenses impacted financial performance.",
        "keyQuotes": [
          "We are committed to advancing innovative medicines to prevent and treat life-threatening diseases",
          "The decrease was primarily driven by an acquired in-process research and development charge of $3.9 billion related to the acquisition of CymaBay"
        ],
        "marketData": {
          "priceOnEarningsDate": 72.87999725341797,
          "priceAfter7Days": 69.41999816894531,
          "priceChangePercent": -4.747529109313169,
          "managementToneScore": 5,
          "earningsBeatScore": 50,
          "priceActionScore": 35,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 41,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q1 2024",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2024,
        "fiscalQuarter": 1,
        "fiscalYear": 2024,
        "quarter": "Q1 2024",
        "reportDate": "2024-03-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-24-000007",
        "filingDate": "2024-02-23",
        "reportDate": "2023-12-31",
        "form": "10-K",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209524000007/gild-20231231.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "stable",
        "revenue": 7114,
        "netIncome": 1444,
        "operatingCashFlow": 8006,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "We continue to see strong demand across HIV treatment and prevention",
        "customerConcentration": 91,
        "geographicBreakdown": {
          "US": 71.7,
          "Europe": 15.9,
          "OtherInternational": 12.4
        },
        "capexAmount": null,
        "capexGrowth": null,
        "partnerships": [
          "Assembly Biosciences collaboration for antiviral therapies",
          "Arcellx collaboration for cell therapy",
          "Arcus collaboration expanded to inflammatory diseases",
          "Compugen licensing agreement"
        ],
        "supplyChainStatus": "tight",
        "regulatoryHeadwinds": [
          "Medicare price negotiation provisions",
          "State-level drug pricing regulations"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": true,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Gilead delivered strong financial performance in 2023, with 6% growth in HIV product sales and continued oncology expansion. The company remains focused on innovative therapeutics while managing pricing pressures and regulatory challenges.",
        "keyQuotes": [
          "We are committed to advancing innovative medicines to prevent and treat life-threatening diseases",
          "Our strategic business development activity reflects our commitment to focus on transformative science"
        ],
        "marketData": {
          "priceOnEarningsDate": 83.23999786376953,
          "priceAfter7Days": 83.98999786376953,
          "priceChangePercent": 0.9010091533489093,
          "managementToneScore": 90,
          "earningsBeatScore": 50,
          "priceActionScore": 55,
          "guidanceAccuracyScoreWeighted": 75,
          "compositeSentimentScore": 61,
          "compositeSentiment": "bullish"
        }
      },
      "quarter": "Q4 2023",
      "quarterInfo": {
        "calendarQuarter": 4,
        "calendarYear": 2023,
        "fiscalQuarter": 4,
        "fiscalYear": 2023,
        "quarter": "Q4 2023",
        "reportDate": "2023-12-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-23-000031",
        "filingDate": "2023-11-07",
        "reportDate": "2023-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209523000031/gild-20230930.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "stable",
        "revenue": 7051,
        "netIncome": 2172,
        "operatingCashFlow": 5837,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": 66,
        "geographicBreakdown": {
          "US": 71.1,
          "Europe": 14.8,
          "OtherInternational": 14.1
        },
        "capexAmount": 370,
        "capexGrowth": null,
        "partnerships": [
          "Arcellx collaboration for CART-ddBCMA",
          "XinThera acquisition",
          "Tmunity acquisition"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "HIV antitrust litigation",
          "Patent challenges for generic manufacturers"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": true,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Gilead delivered strong Q3 performance with stable revenues of $7.05 billion and net income of $2.17 billion. The company continues to focus on oncology and HIV product lines while defending intellectual property and managing legal challenges.",
        "keyQuotes": [
          "We believe these cases are without merit, and intend to vigorously defend ourselves",
          "We are cooperating with this inquiry"
        ],
        "marketData": {
          "priceOnEarningsDate": 74.0999984741211,
          "priceAfter7Days": 75.05999755859375,
          "priceChangePercent": 1.2955453498530491,
          "managementToneScore": 90,
          "earningsBeatScore": 50,
          "priceActionScore": 55,
          "guidanceAccuracyScoreWeighted": 75,
          "compositeSentimentScore": 61,
          "compositeSentiment": "bullish"
        }
      },
      "quarter": "Q3 2023",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2023,
        "fiscalQuarter": 3,
        "fiscalYear": 2023,
        "quarter": "Q3 2023",
        "reportDate": "2023-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-23-000025",
        "filingDate": "2023-08-04",
        "reportDate": "2023-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209523000025/gild-20230630.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "stable",
        "revenue": 6599,
        "netIncome": 1039,
        "operatingCashFlow": 4082,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": 66,
        "geographicBreakdown": {
          "US": 72.5,
          "Europe": 15.6,
          "OtherInternational": 11.9
        },
        "capexAmount": 248,
        "capexGrowth": null,
        "partnerships": [
          "Arcellx collaboration for CART-ddBCMA",
          "XinThera acquisition",
          "Tmunity acquisition"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Patent oppositions in Europe",
          "HIV antitrust litigation",
          "Product liability lawsuits"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "neutral",
        "summary": "Gilead delivered stable Q2 2023 financial performance with solid revenue of $6.6B and net income of $1.04B. The company continues to focus on strategic acquisitions in oncology and cell therapy while defending its patent portfolio and managing ongoing litigation.",
        "keyQuotes": [
          "We continue to invest in innovative technologies and strategic collaborations",
          "Our HIV and oncology portfolios remain strong and competitive"
        ],
        "marketData": {
          "priceOnEarningsDate": 77.06999969482422,
          "priceAfter7Days": 74.41999816894531,
          "priceChangePercent": -3.438434587222234,
          "managementToneScore": 70,
          "earningsBeatScore": 50,
          "priceActionScore": 35,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 48,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q2 2023",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2023,
        "fiscalQuarter": 2,
        "fiscalYear": 2023,
        "quarter": "Q2 2023",
        "reportDate": "2023-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000882095-23-000017",
        "filingDate": "2023-05-03",
        "reportDate": "2023-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/882095/000088209523000017/gild-20230331.htm"
      },
      "insights": {
        "guidanceTone": "positive",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "expanding",
        "revenue": 6352,
        "netIncome": 1010,
        "operatingCashFlow": 1744,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "Continued strong performance in HIV and Oncology segments",
        "customerConcentration": 64,
        "geographicBreakdown": {
          "US": 70.1,
          "Europe": 17,
          "OtherInternational": 12.9
        },
        "capexAmount": 109,
        "capexGrowth": null,
        "partnerships": [
          "Arcellx collaboration for CART-ddBCMA",
          "Tmunity acquisition",
          "Nurix license for NX-0479",
          "AmerisourceBergen",
          "Cardinal Health",
          "McKesson"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Ongoing patent litigation for sofosbuvir",
          "Pre-exposure prophylaxis patent disputes"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Gilead delivered strong Q1 2023 results with robust HIV and Oncology segment growth, significant net income improvement, and continued strategic investments in cell therapy and innovative therapeutics.",
        "keyQuotes": [
          "We are committed to advancing innovative medicines to prevent and treat life-threatening diseases",
          "Completed strategic acquisition of Tmunity, providing preclinical and clinical programs"
        ],
        "marketData": {}
      },
      "quarter": "Q1 2023",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2023,
        "fiscalQuarter": 1,
        "fiscalYear": 2023,
        "quarter": "Q1 2023",
        "reportDate": "2023-03-31"
      },
      "analyzedSuccessfully": true
    }
  ],
  "totalFetched": 12,
  "successfulAnalyses": 11,
  "lastUpdated": "2025-11-26T05:57:41.759Z"
}